Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice

Regulatory Peptides

Volumn 167, Issue 2-3, 2011, Pages 233-238

  Maggio, Edward T ^a   Grasso, Patricia ^b  

^a Aegis Therapeutics   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Acromegaly; Intravail ; Octreotide acetate; Oral delivery; Pharmacokinetics; Transmucosal absorption

Indexed keywords

ACETIC ACID; EXCIPIENT; INTRAVAIL; OCTREOTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG UPTAKE; FEASIBILITY STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SWISS WEBSTER MOUSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL AVAILABILITY; HALF-LIFE; INJECTIONS, SUBCUTANEOUS; MALE; METABOLIC CLEARANCE RATE; MICE; MONOSACCHARIDES; OCTREOTIDE;

MUS;

EID: 79953171104     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.02.009     Document Type: Article

References (19)

1. Pillion D.J., Ahsan F., Arnold J.J., Balasubramanian B.M., Piraner O., Meezan E. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J Pharm Sci 2002, 91:1456-1462.
2. Krause D., Eddy P., Merutka G., MacDonald B. Intranasal pharmacokinetics and bioavailability of ZT-034, a parathyroid hormone analog. JBMR Abstracts, 31st ASBMR Annual Meetings, September 13 2009, Denver, CO, poster# SU0405 2009.
3. Maggio E.T. Intravail®: highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2006, 3:529-539.
4. Rifkin R.A., Maggio E.T., Dike S., Kerr D.A., Levy M. n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon/-β-1b and reduces its immunogenicity. J Neuroimmune Pharmacol 2011, 6:158-162.
5. Novakovic Z.M., Leinung M.C., Lee D.W., Grasso P. Intranasal administration of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept 2009, 154:107-111.
6. Lee D.W., Leinung M.C., Grasso P. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: a study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration. Regul Pept 2010, 160:129-132.
7. Novakovic Z.M., Leinung M.C., Lee D.W., Grasso P. Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels. Diab Obes Metab 2010, 12:532-539.
8. He Y.L., Murby S., Gifford L., Collett A., Warhurst G., Douglas K.T., Rowland M., Ayrton J. Oral absorption of D-oligopeptides in rats via the paracellular route. J Pharm Res 1996, 13:1673-1678.
9. Arnold J.J., Ahsan F., Meezan E., Pillion D.J. Nasal administration of low molecular weight heparin. J Pharm Sci 2002, 91:1707-1714.
10. Ahsan F., Arnold J.J., Yang T., Meezan E., Schwiebert E.M., Pillion D.J. Effect of the permeability enhancers, tetradecylmaltoside and dimethyl-beta-cyclodestranm, on insulin morement across human bronchila epithelial cells (16HBE14o-). Eur J Pharm Sci 2003, 20:27-34.
11. Arnold J.J., Fyrberg M.D., Meezan E., Pillion D.J. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside. J Pharm Sci 2010, 99:1912-1920.
12. He Y.L., Murby S., Warhurst G., Gifford I., Walker D., Ayrton J., Eastmond R., Rowland M. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of olyl(ethylene glycol) and D-peptides. J Pharm Sci 1998, 87:626-633.
13. Ahsan F., Arnold J., Meezan E., Pillion D.J. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res 2001, 18:1742-1746.
14. Pillion D.J., Atchison J.A., Garguilo C., Wang R.X., Wang P., Meezan E. Insulin delivery in nosedrops: new formulations containing alkyglycosides. Endocrinology 1994, 135:2386-2391.
15. Ahsan F., Arnold J.J., Yang T., Meezan E., Schwiebert E.M., Pillion D.J. Effects of the permeability enhancers tetradecylmaltoside and dimethyl-B-17 cyclodextran, on insulin movement across human bronchial epithelial cells. Eur J Pharm Sci 2003, 20:27-34.
16. Plusquellec Y., Campistron G., Staveris S., Barre J., Jung L., Tillement J.P., Houin G. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Pharmacodyn 1987, 15:225-239.
17. Yin O.Q., Tomlinson G., Chow A.H., Chow M.S. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clin Pharmacokinet 2003, 42:179-192.
18. Takamatsu N., Welage L.S., Hayashi Y., Yamamoto R., Barnett J.L., Shah V.P., Lesko L.J., Ramachandran C., Amidon G.L. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Eur J Pharm Biopharm 2002, 53:37-47.
19. Chen S.C., Eiting K.T., Li A.A.W., Lamharzi N., Quay S.C. Peptide drug permeation enhancement by select classes of lipids. 45th American Society for Cell Biology Meeting, December 10-14, 2005; San Francisco 2005, (late abstract).